key: cord-0719115-vn3zaqmz
authors: Deng, Man-Ling; Chen, Yong-Jun; Yang, Mei-Ling; Liu, Yi-Wen; Chen, Hui; Tang, Xiao-Qing; Yang, Xue-Feng
title: COVID-19 combined with liver injury: Current challenges and management
date: 2021-05-26
journal: World J Clin Cases
DOI: 10.12998/wjcc.v9.i15.3487
sha: fa13c4794f7f53bb4ecd1644000dfb1243b7aae1
doc_id: 719115
cord_uid: vn3zaqmz

Coronavirus disease 2019 (COVID-19) combined with liver injury has become a very prominent clinical problem. Due to the lack of a clear definition of liver injury in patients with COVID-19, the different selection of evaluation parameters and statistical time points, there are the conflicting conclusions about the incidence rate in different studies. The mechanism of COVID-19 combined with liver injury is complicated, including the direct injury of liver cells caused by severe acute respiratory syndrome coronavirus 2 replication and liver injury caused by cytokines, ischemia and hypoxia, and drugs. In addition, underlying diseases, especially chronic liver disease, can aggravate COVID-19 liver injury. In the treatment of COVID-19 combined with liver injury, the primary and basic treatment is to treat the etiology and pathogenesis, followed by support, liver protection, and symptomatic treatment according to the clinical classification and severity of liver injury. This article evaluates the incidence, pathogenesis and prevention and treatment of COVID-19 combined with liver injury, and aims to provide countermeasures for the prevention and treatment of COVID-19 combined with liver injury.

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally, resulting in an ongoing pandemic [1] . As of February 15, 2021, the World Health Organization (WHO) has reported a total of 108579352 confirmed cases of COVID-19 in 184 countries by world region, with a cumulative total of 2396408 deaths [2] . The main target organ of SARS-CoV-2 infection is not only the lung but also many extrapulmonary tissues [3] . Among them, COVID-19 combined with liver injury has become a very prominent clinical problem and has garnered great attention [4] . The author of this article once reported that about one-fifth of the 48 COVID-19 patients have abnormal liver function [5] . At present, the prevention and treatment of COVID-19 combined with liver injury face many challenges, and several key problems need to be solved. For example, the diagnosis of COVID-19 combined with liver injury. Due to the inconsistent diagnostic criteria, a series of problems have arisen in the diagnosis and treatment of COVID-19 combined with liver damage. If the diagnostic criteria are too low, it may lead to overtreatment in clinical practice [6] . Another problem is the study of pathogenesis. It is necessary to determine whether SARS-CoV-2 can directly invade the liver, especially when angiotensin-converting enzyme 2 (ACE2) appears to be negligibly expressed on liver cells [4] . In addition, the mechanisms underlying liver dysfunction in COVID-19 patients are not fully understood; it may be multifactorial and related to hyperinflammation, dysregulated immune responses, abnormal coagulation, and drugs [4] .

This article provides an additional view of the incidence, pathogenesis, prevention, and treatment of COVID-19-associated liver injury and explores the contemporary management modalities.

At present, the evaluation parameters for studying the incidence of COVID-19 liver injury are different. The liver function parameters generally include alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TB) [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Some also include alkaline phosphatase (ALP), γ-glutamyl transpeptidase (γ-GT), and so on [5] . Liver injury in COVID-19 patients lacks a clear definition [6] . Some researchers define liver damage as liver enzyme levels above the upper limit of normal (ULN)[5,7] and albumin below the lower limit of normal [5] ; other researchers define it as liver enzyme levels 2 or 3 times or even 5 times higher than the ULN [8, 9] . China's "New Coronavirus Pneumonia with Liver Injury Prevention, Diagnosis and Treatment Program" defined as COVID-19 combined with liver injury in the following situations, COVID-19 patients with or without underlying liver disease, the upper limit of serum ALT or AST higher than normal is called COVID-19 with abnormal liver function; ALT or AST ≥ 3 times the ULN or TB ≥ 2 times is called COVID-19 with liver injury [10] . American College of Gastroenterology and British Society of Gastroenterology clinical guidelines define liver injury as an increase in ALT or AST by at least 3 × ULN, or an increase in alkaline phosphatase, TB, or direct bilirubin by at least 2 × ULN [11, 12] . Due to the different parameters and criteria for evaluating liver function in patients with COVID-19, the incidence of liver injury varies widely across studies, from 4.8% to a striking 78% [13] . The difference in the incidence of liver injury in different studies is also related to the statistical time point. For example, Ding et al [14] calculated that the abnormal liver function rate of COVID-19 patients at hospitalization admission was 46.2% (958/2073), and the incidence of liver injury was 5.1% (105/2073); Statistics during hospitalization (during disease progression) showed that the abnormal liver function rate was 61.8% (1282/2073), and the incidence of liver injury was 14.3% (297/2073).

In short, due to the unclear definition of liver injury, the different selection of evaluation parameters, the inconsistent statistical time points (i.e. on admission or during disease progression), the incidence of COVID-19 combined with liver injury is extremely inconsistent in different research reports. Therefore, some academics suggest that researchers pay close attention to the terminology and its definition to avoid ambiguity in future analyses and overtreatment in clinical practice[6].

The mechanism of COVID-19 combined with liver injury is complex including direct injury, immune injury, ischemia and hypoxia, and drug injury. In addition, underlying diseases, especially chronic liver disease, can aggravate COVID-19 liver injury. The new coronavirus, like SARS virus, can use ACE2 as a receptor for cell entry [17] [18] [19] . There are differences in the expression of ACE2 in different tissues and even different cells in the same tissue [20, 21] . Han et al [20] combined the Genotype-Tissue Expression and The Cancer Genome Atlas databases and found that ACE2 is most highly expressed in the small intestine, and the expression level is lower in the spleen, brain, muscle, pituitary, and skin tissues. It is also expressed in other tissues such as the kidney, heart, liver, and other tissues [20] . Chai et al [21] used the single-cell RNA sequencing method to determine that the expression of ACE2 in hepatic bile duct cells was significantly higher than that of hepatocytes (59.7% vs 2.6% of cells), and the average expression level of ACE2 mRNA in bile duct cells was 20 times higher than that of hepatocytes. Thus, it is speculated that the SARS-CoV-2 virus enters the bile duct cells through ACE2 to cause liver injury. However, based on current research, ACE2-expressing organs do not equally participate in COVID-19 pathophysiology, indicating that other mechanisms are involved in orchestrating cellular infection resulting in tissue injury [22] . However, clinical data show that some patients with COVID-19 do not have a significant increase in the serum indicators of bile duct cells such as ALP and γ-GT but do have increased ALT and AST levels, reflecting liver cell injury [23] . These data suggest that the specific causes of liver cell injury caused by SARS-CoV-2 virus still need a lot of research to clarify its mechanism. Other receptors ( e.g., dipeptidyl-peptidase 4, transmembrane serine protease 2) may also mediate the entry of SARS-CoV-2 virus into liver cells to cause liver injury [19, 24] 

As aforementioned, the main target organ of new coronary pneumonia is the lung, and immune dysfunction is one of the leading causes of lung injury. At present, the most discussed immune injury is the "cytokine storm", which is infection of the organism by microorganisms. Subsequent immune system-related reactions can further cause multiple organ injuries and acute respiratory distress syndrome to induce liver hypoxia and damage liver cells. Both of these reasons can lead to abnormal liver function indicators in the laboratory [25] . Studies have pointed out that in critically ill patients, the abnormal ratio and degree of cytoinflammatory factors are significantly higher than those in moderate to severe patients [26, 27] , accompanied by an increase in the proportion of neutrophils and lymphopenia [28] . Nevertheless, in critically ill patients, the probability and degree of liver injury are significantly higher than those of mild to moderate patients. In a large cohort of 5771 people, it was found that elevated ALT and AST were accompanied by lymphopenia and increased neutrophil count [28] . A retrospective study by Huang et al [29] found that the increase of cytoinflammatory factors, namely interleukin (IL)-1, IL-6, IL-8, and IL2R is negatively correlated with the reduction of albumin, and the liver is the main organ for albumin synthesis. This also further illustrates that the "cytokine storm" may be one of the potential causes of liver injury (Figure 1 ). In a recent study in the United States, it was noted that the systemic inflammatory response was excessive in patients with acute liver failure, which was manifested by significantly increased levels of inflammatory markers and cytokines, and the elevated levels of inflammatory markers were linearly related to the number of organ failures. The authors believed that it may be the inflammatory response in patients with new coronary pneumonia that triggers the occurrence of acute liver failure in patients with potential chronic liver disease[30]. 

The 

COVID-19 combined with liver injury has become a very prominent clinical problem. Timely detection and treatment are particularly important for the prevention and treatment of COVID-19 combined with liver injury.

Since SARS-CoV-2 infection affects the whole body, which is necessary to monitor the body tissues and organs of all COVID-19 patients, including liver function. Routine examination items include liver function, various hepatitis virus markers, inflammatory factors (such as IL-6, C-reactive protein, procalcitonin), and bleeding coagulation function. If COVID-19 combined with liver injury is considered to be caused by basic diseases, blood glucose, blood lipids and other organ function indicators, which are such as B-type natriuretic peptides, N-terminal fragment brain natriuretic peptides or high-sensitivity troponin T must be monitored. Due to hypoxia progression may also be insidious in that patients may not be short of breath despite relatively low blood oxygen levels [43] . Therefore, whether patients with COVID-19 have breathing difficulties, blood oxygen saturation should be routinely monitored.

When the liver function of COVID-19 patients is normal before hospitalization admission, and abnormalities gradually appear during the treatment process, the drug-induced liver injury should be considered[10]. The diagnosis of drug-induced liver injury is exclusive. It needs to be combined with a medical history and related examinations to rule out other liver diseases, then causality assessment is used to determine the degree of correlation between liver injury and suspected drugs. For patients with suspected drug-induced liver injury, consideration should be given to discontinuing or reducing the use of suspicious drugs. For more details, please refer to the 2015 version of the "Guidelines for the diagnosis and treatment of drug-induced liver injury" for treatment [46] .

If patients with chronic hepatitis B receive long-term antiviral therapy, the drug should not be stopped; those who need hormone therapy should also receive highefficiency and low-resistance anti-hepatitis B drugs (e.g., entecavir, tenofovir dipivoxil or propofol tenofovir) inhibit HBV replication from preventing HBV replication reactivation or hepatitis B attack [10] . For patients with hypertension, blood pressure needs to be closely monitored and maintained at a stable level [47] . For patients with coronary heart disease, it is recommended to actively control heart rate, stabilize hemodynamics, and protect the heart and other related treatments [47] . When COVID-19 patients have diabetes at the same time, for mild COVID-19 patients, if the patient's blood sugar is stable, the original hypoglycemic regimen can be used to control blood glucose. For critically severe COVID-19 patients, insulin pump is recommended to lower blood sugar, and the blood glucose range. It is recommended that fasting blood glucose be 7.8-10.0 mmol/L, and blood glucose should be controlled at 7.8-13.9 mmol/L 2 h after meal [47, 48] .

There is currently no evidence that hepatoprotective drugs can improve the prognosis of patients, and patients with mild liver biochemical abnormalities generally do not need to use hepatoprotective drugs [10] . For patients with acute liver injury, the changes in liver function should be closely monitored, and 1-2 kinds of liver protection drugs with less side effects should be selected as appropriate [10] . Specific liver protection drugs include anti-oxidant hepatoprotective drugs and detoxification liver protection drugs such as reduced glutathione, glycyrrhizic acid liver protection drugs such as diammonium glycyrrhizinate capsules, magnesium magnesium isoglycyrrhizinate injection, liver cell membrane protection liver protection drugs such as polyene phosphatidyl choline, anti-oxidant hepatoprotective drugs such as silibinin and bicyclol, and cholinergic hepatoprotective drugs such as ursodeoxycholic acid and S-adenosylmethionine [49] . For patients with acute liver failure, actively carry out etiological treatment and symptomatic and supportive treatment. For details, please refer to China's "Guidelines for Diagnosis and Treatment of Liver Failure (2018 Edition)" [50] . 

Antiviral therapy is a basic treatment. If the liver injuries associated with COVID-19 is not caused by antiviral drugs, antiviral treatment should be given as soon as possible to inhibit virus replication and accelerate virus clearance. The eighth edition of the diagnosis and treatment plan recommends that the following drugs can continue to be tried and further evaluated in clinical applications[32]: α-interferon, ribavirin, CQ phosphate, and arbidol.

The current consensus is that antiviral drugs with potential antiviral effects should be used within 10 d after the onset of disease, because the virus is in the replication stage at this stage [51] , and the combination use of two antiviral drugs is advocated [52] .

Due to the unclear efficacy, some antiviral drugs are not recommended or cannot be used alone [53, 54] . The eighth edition of the diagnosis and treatment plan does not recommend the use of lopinavir/ritonavir and ribavirin alone, nor the use of HCQ or the combined use of azithromycin [32] .

The efficacy of some drugs needs to be screened. Remdesivir is a drug officially approved by the United States Food and Drug Administration for the treatment of hospitalized patients with COVID-19, but the clinical efficacy results are conflicting [55, 56] .

When using antiviral drugs, pay attention to drug adverse reactions, con-traindications, and interactions with other drugs. It is not recommended to use more than 3 antiviral drugs at the same time [10] .

If there are intolerable side effects such as liver injury, the relevant drugs should be stopped, and the convalescent plasma antiviral can be used when conditions permit. According to the currently available treatment data, plasma therapy for recovered patients is very effective for patients who still have viruses in their bodies [57, 58] . In view of limited source of plasma sources in recovery patients from COVID-19, the development and use of therapeutic monoclonal antibodies against the new coronavirus is of great significant [59, 60] .

Currently, treatments for cytokine storm caused by new coronavirus infection include: the IL-6 and receptor antagonists, blood purification, glucocorticoids, etc. Studies by Shruti Gupta and others found that among critically ill patients with new coronavirus pneumonia, patients treated with IL-6 receptor antagonist-cilizumab had a lower risk of in-hospital death during the first 2 d of admission to the intensive care unit. Patients treated with cilizumab early[61]. Stutuzumab is a drug that directly targets IL-6, which can directly bind to IL-6 to neutralize the biological effects caused by IL-6[62]. The efficacy of these two drugs on the cytokine storm caused by SARS-CoV-2 still needs further clinical trials to verify[63]. Since both cilizumab and stutuzumab can cause liver damage[63], it is recommended to avoid severe and critical COVID-19 patients with liver damage as much as possible. Glucocorticoids can be used to treat cytokine storm within a short period of time (generally recommended 3-5 d, no more than 10 d).

For patients with drug-induced liver injury without contraindications, especially patients with severe liver injury, the early use of hormones is effective and safe [64] . On September 2, 2020, WHO also published a guidance document on the role of corticosteroids in the treatment of COVID-19[65]. In addition, blood purification can also be used for the early and mid-term treatment of cytokine storm in severe and critical COVID-19 patients with liver injury[10,32].

The prevention and treatment of COVID-19 combined with liver injury faces many challenges. First, the definition of COVID-19 combined with liver injury is not clear, the selected parameters and the statistics time are inconsistent, and the final conclusions on the incidence rate are consistent. Second, the etiology and mechanism of COVID-19 combined liver injury are not clear and need to be studied in depth. Third, there is a lack of effective treatment methods. The development and use of therapeutic monoclonal antibodies against the new coronavirus is of great significance.

SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19

World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard Data

Extrapulmonary manifestations of COVID-19

COVID-19-associated liver injury: from bedside to bench

COVID-19 and the cardiovascular system

Prevalence of diabetes mellitus in 2019 novel coronavirus: A metaanalysis

Malvy D; COVERAGE study group. Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial)

Chinese Society of Infectious Diseases

Virological assessment of hospitalized patients with COVID-2019

Saudi Critical Care Trials Group. Interferon Beta-1b and Lopinavir-Ritonavir for Middle East Respiratory Syndrome

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Remdesivir for the Treatment of Covid-19 -Final Report

Covid-19: Remdesivir has little or no impact on survival, WHO trial shows

Potential specific therapies in COVID-19

Covid-Plasma Task Force. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial

Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents?

Analysis of related patents on coronavirus monoclonal antibody therapy

STOP-COVID Investigators. Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19

Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19

Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review

Corticosteroid therapy in drug-induced liver injury: Pros and cons

Corticosteroids for COVID-19